Close Menu

NEW YORK (360Dx) – Researchers at the University of Virginia School of Medicine and the University of Florida College of Medicine have developed a method to minimize false-negative test results that occur during immunoassay screening for benzodiazepine, a class of psychoactive drugs.

The method, described this week in The Journal of Applied Laboratory Medicine optimizes absorbance cutoff values, which are thresholds for determining whether a sample is sent for mass spectrometry confirmatory testing.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.